EFTA02627351.pdf

From: eva Sent: Tuesday, January 29, 2019 6:22 PM To: Subject: Re: Hi, Please note, my email address has changed to mailto: On Jan 29, 2019, at 12:41PM, J <[email protected] <mailto:[email protected]> wrote: e From:la <111 <mailto Date: ue, an , 9 at 6:28 PM Subject: Re: To: Jeffrey <[email protected] <mailto:[email protected]» Sorry, they just clarified: she was advised to do chemo + radiation regardless of the targeted drugs. Their question is which drugs to add: - herceptin + chemo + radiation - perjeta + chemo + radiation - herceptin+perjeta + chemo + radiation > On Jan 29, 2019, at 11:50 AM, @icloud.com <mailto icloud.com> > wrote: > Patient is 29y.o. > Breast cancer left breast: > Tlc N1 MO G2 > Her2 score 3+ > ER-: PP=1 15=1 Score=2 > PR- : PP=1 IS=1 Score=2 > BRCA test showed no gene mutations. > Bilateral mastectomy has been done + 6 lymph nodes removed on the left side. > Their treatment choices are whether to do Herceptin alone, or Perjeta alone, or both together? EFTA_R1_01842272 EFTA02627351  please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected] <mailto:[email protected]> , and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved 2 EFTA_R1_01842273 EFTA02627352